Verona Pharma
VRNA
VRNA was delisted on the 6th of October, 2025.
28 hedge funds and large institutions have $213M invested in Verona Pharma in 2020 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 8 increasing their positions, 3 reducing their positions, and 5 closing their positions.
533% more capital invested
Capital invested by funds: $33.6M → $213M (+$179M)
200% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 5
167% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 3
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
56% more funds holding
Funds holding: 18 → 28 (+10)
1.48% more ownership
Funds ownership: 6.74% → 8.22% (+1.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$35.2M |
| 2 |
O
OrbiMed
New York
|
+$30.7M |
| 3 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$26.9M |
| 4 |
PA
Perceptive Advisors
New York
|
+$20M |
| 5 |
A
Abingworth
London,
United Kingdom
|
+$10.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VP
venBio Partners
San Francisco,
California
|
-$1.78M |
| 2 |
WS
Wedbush Securities
Los Angeles,
California
|
-$455K |
| 3 |
BBVA
Banco Bilbao Vizcaya Argentaria
Madrid,
Spain
|
-$303K |
| 4 |
DADC
D.A. Davidson & Co
Great Falls,
Montana
|
-$203K |
| 5 |
CCFM
Clear Creek Financial Management
Silverdale,
Washington
|
-$175K |
VRNA Hedge Fund Activity: Q3 2020 in Review
28 of the 4,961 institutional investors tracked by Wall St. Rank reported a position in Verona Pharma (VRNA) for Q3 2020, worth a combined $213M — up 533% from $33.6M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new VRNA positions and 5 closed out — a net gain of 10 holders — while 8 added to existing stakes and 3 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $35.2M. The largest seller was venBio Partners, cutting an estimated $1.78M.
- 28 institutional investors held Verona Pharma (VRNA) as of Q3 2020, up from 18 in Q2 2020.
- Funds reported $213M of Verona Pharma stock for Q3 2020, up 533% quarter-over-quarter.
- 15 funds opened new Verona Pharma positions in Q3 2020 and 5 closed out, a net change of +10 holders.
- The largest Verona Pharma buyer in Q3 2020 was RA Capital Management, an estimated $35.2M added.
- The largest Verona Pharma seller in Q3 2020 was venBio Partners, an estimated $1.78M sold.
Based on aggregated 13F filings for Q3 2020.